Articles On Noxopharm (ASX:NOX)

Noxopharm (ASX:NOX) has announced the publication in an abstract form of the latest survival data from the LuPIN study ahead of a formal presentation to the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposiu...

ShareCafeHidden Gems Webinar Recap – NOX, VMS, EMU, RXL Catch up on the full webinar with presentations from Noxopharrm (ASX:NOX), Venture Minerals (ASX:VMS), EMU Resources (ASX:EMU) & Rox Resources (ASX:RXL) Hidden Gems Webinar Recap...

ShareCafeNoxopharm (ASX:NOX) – Hidden Gems Webinar Presentation     Presenter – Dr. Graham Kelly Founder & CEO  – Noxopharm Limited is a clinical-stage drug development company that focuses on the research and development of drugs to e...

The Noxopharm Ltd (ASX:NOX) share price launched up more than 7% today as the company released its report for the fourth quarter December 2020. At the time of writing, the Noxopharm share price trading up 7.69% at 63 cents. Let’s take a cl...

Noxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

13 Jan 2021 - Drug development company, Noxopharm (ASX:NOX) reports that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth…

Noxopharm CEO Dr Graham Kelly speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

While the S&P/ASX 200 Index (ASX: XJO) is slipping today, the Australian clinical-stage drug developer Noxopharm Ltd (ASX: NOX) is bucking the trend with its shares rising. At the time of writing, the Noxopharm share price is up 14.13%...

ShareCafeAustralia…One Hour In…ASX up 52 points ASX200 up 52 points (0.8%) to 6685.   Afterpay (+1.5%); Reserve Bank governor Philip Lowe said the bank was “unlikely” to conclude that Afterpay and other BNPL firms would have to remove thei...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has completed a $23 million share placement to professional, institutional, and sophisticated investors.

ASX-listed drug developer is Noxopharm has put a $20 million equity raising to investors in an effort to fund studies slated for next year. 

Australian drug development company Noxopharm Limited (ASX: NOX) has announced a major breakthrough this morning on its DARRT cancer therapy drug.  The announcement shot the share price of NOX up by 11% to 63 cents at the opening bell. Wha...

Noxopharm (ASX:NOX) has announced its investigative cancer therapy Veyonda will be trialed with Bristol-Myers Squibb's immunotherapy OPDIVO (nivolumab).

The Noxopharm Ltd (ASX: NOX) share price has started the week in a positive fashion. At one stage today the clinical-stage drug development company’s shares were up as much as 8% to 54 cents. The Noxopharm share price has since pulled back...

05 Nov 2020 - Clinical-stage drug development company Noxopharm Limited (ASX:NOX) has partnered with Hudson Institute of Medical Research and a collaboration with The Australian Na…

Burgeoning medtech company Noxopharm (ASX: NOX) is making strides in the effort race to find a treatment for COVID-19. The Sydney-based clinical-stage drug development company has filled the first two cohorts for its trial of Veyonda, an...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the final patient has completed treatment in the LuPIN study.

Australian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal approval for immediate initiation of Veyonda®’s clinical trial in COVID-19 patients in Europe. Following the key update, the Company’s...

Clinical-stage drug development player, Noxopharm Limited (ASX:NOX) has recently announced peer-reviewed publication of the LuPIN trial data in the international journal, European Urology Oncology. According to Noxopharm, the publication o...

New important pre-clinical data from two independent laboratories has validated the potential of Noxopharm Limited’s (ASX:NOX) idronoxil (active ingredient in Veyonda®) to restore the cancer-fighting immune function within ‘COLD&rsquo.....

New important pre-clinical data from two independent laboratories has validated the potential of Noxopharm Limited’s (ASX:NOX) idronoxil (active ingredient in Veyonda®) to restore the cancer-fighting immune function within ‘COLD&rsquo.....

The Noxofarm Ltd (ASX: NOX) share price soared after positive results regarding its cancer treatment drug, Veyonda, were released this morning. The immuno-oncology drug development company saw its share price rise 12% to 37 cents on the ne...

Noxopharm Limited (ASX:NOX) is trading ~5 per cent higher (as at 12:01 PM AEST) following the release of its Corporate Presentation for the Reach Markets Virtual Event. Noxopharm is focused on arguably the biggest prize in the pharma indus...

Nyrada (ASX: NYR) has received “encouraging” results from a lab-based cholesterol-lowering study, for the drug it hopes to use to treat hypercholesterolemia — or high cholesterol. The preclinical study used healthy donor human white blood c...

Noxopharm (ASX:NOX) has announced the commencement of its NOXCOVID clinical program with a planned phase one trial in Europe.

Australian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update the commencement of NOXCOVID clinical trial program in Europe, focusing on safety and proof-of principle endpoints of Veyonda® as a potentia...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Summary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a treatment for end-stage prostate cancer at ASCO 2020 Annual Meeting. Highly encouraging interim data from the Phase 1b/2a LuPIN clinical t...

Noxopharm (ASX: NOX) has updated on its presentation of two sets of clinical trial data relating to the development of NOX66 (Veyonda) as a treatment of end-stage cancer.

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

Marking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre-IND (Investigational New Drug) submission with the U.S. Food and Drug Administration (FDA) for a Veyonda® clinical trial in COVID-19 (SARS-...

Noxopharm (ASX:NOX) has lodged a pre-Investigational New Drug (pre-IND) submission with the US FDA for a clinical trial of its Veyonda in patients with COVID-19 infection.

Shares in Noxopharm Ltd (ASX:NOX) traded more than 40% higher on Tuesday afternoon after the company received advice from the US Food and Drug Administration (FDA) that it should lodge a pre-Investigational New Drug (pre-IND) submission for...

Noxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards progressing its oncology programs as well as its recent move into infection.

Our summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) announces it will undertake a 1 for 2.5 fully underwritten, pro-rata entitlement offer of new fully paid ordinary shares at an Offer Price of $0...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Biotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-stage prostate cancer as suggested by the latest radiographic review of DARRT-1 clinical study, supporting the Company’s belief in the anti-ca...

In a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, p...

Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study and says it shows a major benefit from a combination of Veyonda and low-dose radiotherapy.

Our summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) today has released details of the radiographic review of its DARRT-1 clinical study. What are the key highlights? The review shows a major be...

Clinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the active ingredient in Veyonda® - idronoxil, blocks the STING (Stimulator of Interferon Genes) signalling pathway associated with the type of...

Biotech company Noxopharm (ASX: NOX) will seek approval from the US Food and Drug Administration for a clinical study involving its end-stage prostate cancer drug Veyonda on early-stage COVID-19 patients with the aim of blocking the progres...

Noxopharm (ASX:NOX) is the latest biotech to announce it will test its drug against COVID-19. So how exactly does an anti-prostate cancer drug work for COVID-19? Noxopharm says it is all about one signalling pathway — the STING (Stimulator...

Noxopharm (NOX:ASX) has announced the active ingredient of its investigational therapy Veyonda - idronoxil - could block the hyper-inflammation stemming from the infection that is believed responsible for deaths in patients with COV...

Australian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of Medical Research in Melbourne, has identified anti-inflammatory properties of idronoxil, consistent with reducing a ‘cytokine storm’ whic.....